• Citer

Trends in virological and clinical outcomes in individuals with HIV-1 infection and virological failure of drugs from three antiretroviral drug classes: a cohort study.

par Pursuing Later Treatment Options II (PLATO II) Project Team for the Collaboration of Observational HIV Epidemiological Research Europe (COHERE), Dominique;Observational HIV Epidemiological Research Europe (COHERE) Group, Rebecca;Costagliola, Bruno;Lodwick, Carlo;Ledergerber, Ard;Torti, Daniel;van Sighem, Amanda;Podzamczer, Maria;Mocroft, Bernard;Dorrucci, Andrea;Masquelier, Klaus;De Luca, Stéphane;Jansen, Niels;De Wit, Gerd ;Obel, Giota;Fätkenheuer, Cristina;Touoloumi, Antonella;Mussini, Christoph;Castagna, Federico;Stephan, Robert;Garcia Colominas, Xavier ;Zangerle, Santiago;Duval, Laurence;Pérez-Hoyos, Jade;Meyer, Céline;Ghosn, Jesper;Fabre-Colin, Geneviève;Kjaer, Jesper;Chêne, Andrew;Grarup, ;Phillips,
Référence Lancet. Infectious diseases, 12, 2, page (119-127)
Publication Publié, 2012-02

Article révisé par les pairs

• Accès en ligne
• Détails
• Contenu
• Statistiques

Résumé :

Limited treatment options have been available for people with HIV who have had virological failure of the three original classes of HIV antiretroviral drugs-so-called triple-class virological failure (TCVF). However, introduction of new drugs and drug classes might have improved outcomes. We aimed to assess trends in virological and clinical outcomes for individuals with TCVF in 2000-09.